Clinical trial
Eflornithine To Prevent Cervical Cancer in Patients With Cervical…
NCT00006079 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00006079 |
|---|---|
| Title | Eflornithine To Prevent Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia |
| Official title | A Randomized Double-Blind Study of Alpha-Difluromethylornithine (DFMO) Versus Placebo in Patients With Cervical Intraepithelial Neoplasia (CIN) Grade 2-3 |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer, Precancerous Condition |
| Intervention type | Drug, Other |
| Interventions | Eflornithine, Placebo |
| Enrollment | 150 |
| Start date | Jun 19, 1998 |
| Primary completion | Apr 27, 2004 |
| Completion | Apr 27, 2004 |
| First posted | May 26, 2004 |
| Last update posted | Oct 25, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: